Physician profile
Ricardo Serrano
NPI 1629180351
$19,539.88
in general payments reported to CMS, 2019-2025
28 companies · $1,582 in 2025
The $1,582 reported for 2025 was more than what 91% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,202 · 2020: $2,103 · 2021: $3,681 · 2022: $2,777 · 2023: $2,142 · 2024: $2,052 · 2025: $1,582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,776.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $6,717.68 | 2019-2025 | Xarelto, Spravato |
| Astrazeneca Pharmaceuticals LP | $3,737.29 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,832.70 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,135.57 | 2019-2023 | |
| Amgen INC. | $1,053.30 | 2019-2025 | Evenity, Krystexxa |
| Lilly USA, LLC | $1,014.94 | 2019-2024 | Mounjaro, Jardiance |
| Radius Health, INC. | $598.17 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $577.64 | 2019-2023 | Belsomra, Janumet |
| Boehringer Ingelheim Pharmaceuticals, INC. | $471.24 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $265.74 | 2022-2023 | |
| Kowa Pharmaceuticals America, INC. | $257.96 | 2019-2024 | Livalo |
| Exact Sciences Corporation | $214.01 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $210.24 | 2019-2022 | |
| Pfizer INC. | $208.94 | 2019-2023 | |
| Daiichi Sankyo INC. | $206.45 | 2021-2023 | Injectafer |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $197.94 | 2023-2024 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $152.53 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $128.66 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $125.59 | 2025 | Voquezna |
| Esperion Therapeutics, INC. | $125.00 | 2024 | Nexlizet, Nexletol |
| Wright Medical Technology, INC. | $99.88 | 2019 | |
| Azurity Pharmaceuticals, INC. | $68.23 | 2024-2025 | Horizant |
| Biogen, INC. | $34.24 | 2021 | |
| Genentech USA, INC. | $27.33 | 2019 | |
| Photonicare INC | $26.88 | 2023 | Otosight Middle Ear Scope |
| Almatica Pharma LLC | $19.01 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.55 | 2021 | |
| Eisai INC. | $15.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ricardo Serrano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.